Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists for mental health conditions, announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. The full press release is available at https://ibn.fm/1QdP7.
This announcement comes as Helus Pharma advances its pipeline of proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways believed to promote neuroplasticity. The company’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. Helus Pharma also maintains an extensive research portfolio of investigational NSAs targeting the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions.
The Jefferies Global Healthcare Conference is a prominent industry event that attracts investors, analysts, and healthcare leaders. Helus Pharma’s participation provides a platform to discuss its clinical programs and strategic vision. The company’s focus on developing synthetic molecules intended to provide durable improvements in mental health could address significant gaps in current treatment options. Major depressive disorder and generalized anxiety disorder affect millions worldwide, and existing therapies often have limited efficacy or significant side effects.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The company aims to improve the treatment landscape with class-leading data from its NSA candidates. For updates, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
The implications of Helus Pharma’s progress are significant for patients and the mental health industry. If HLP003 successfully completes Phase 3 trials and gains approval, it could offer a new adjunctive treatment option for major depressive disorder, potentially improving outcomes for those who do not respond adequately to current antidepressants. Similarly, HLP004 could provide a novel approach for generalized anxiety disorder. The Breakthrough Therapy Designation underscores the FDA’s recognition of the potential for HLP003 to address a serious condition with unmet medical need. Investors and healthcare professionals will be closely watching the company’s presentations at the conference for updates on trial timelines and data.
